Exclusive extracts from this 69-page-long report:
- Who are the key players?
The industry is split between a handful of large, deep-pocketed companies and a myriad of small-scale, specialised players. In Europe, for instance, 95% of all medtech firms are SMEs.
The industry manufactures and markets four major categories of devices:
-imaging devices (in-vivo diagnostics): X-ray machines, CT scanners, MRI systems, ultrasounds, etc.
-non-imaging (in-vitro) diagnostics: blood pressure measuring equipment, tissue and molecular tests, etc. [...]
Groups analysed in this report include: Medtronic, Abbott Laboratories, Johnson & Johnson – Medical Devices, Koninklijke Philips – Royal Philips, GE Healthcare, Siemens Healthineers, Stryker, Roche – Diagnotics, Becton, Dickinson and Company, and Boston Scientific.
- What are the players' strategies?
Medtronic is eyeing increased opportunities in under-penetrated emerging markets such as India and China while, at the same time, tapping demand for value-based healthcare in mature markets. This means the company is expanding telemedicine products in emerging economies and, in mature markets, is shifting its delivery model to outcomes-based partnerships with insurers and hospitals. […]
- What are the players' key growth and profitability drivers?
The acquisition of St. Jude Medical catapulted Abbott's sales from €18.5bn in 2016 to €24.3bn in 2017. This inorganic development was further boosted by growth momentum in established pharmaceuticals and diagnostics. The acquisition of St. Jude was primarily reflected in Abbott's Cardiovascular and Neuromodulation (medtech) unit, whose sales jumped to €7.9bn in 2017, from €2.6bn the previous year. [...]